§ Claim under review · Health
"Scientists just proved magic mushrooms can reverse cellular aging by up to 57%"
Verdict
Source exists but framing is misleading
Confidence
HighSummary
The 57 percent number is real, but the headline misrepresents what it means. A 2025 study in the journal npj Aging by researchers at Emory and Baylor found that human cells in a lab dish, treated with psilocin, could divide about 57 percent more times before shutting down. That is a delay in cellular aging, not a reversal, and the cells still aged out in the end. The 57 percent figure came from the highest concentration tested, roughly hundreds of times more than what circulates in a person's blood after taking psilocybin. A separate part of the study found aged mice given monthly high doses survived better than untreated mice, 80 percent versus 50 percent, but that trial was not blinded and used doses never given to humans. No human has been shown to become biologically younger from psilocybin, and nothing here shows that eating magic mushrooms does this. The research is genuinely interesting and worth following, but "scientists proved" is not an accurate description of a first-of-its-kind preclinical study.
The readings
key figures from the evidencecellular lifespan extension, 100 μM psilocin, fetal lung fibroblasts
cellular lifespan extension, 10 μM psilocin dose
Why this verdict
Evidence
The 57% figure is real and traceable to a specific line in a real peer-reviewed paper. It does not describe aging reversal in humans. In the cell experiments, psilocin treatment at 10 μM resulted in a 29% extension of cellular lifespan, characterized by delayed exhaustion of proliferative potential, increased cumulative population doublings, and decreased population doubling time, compared to vehicle. Results were more striking using a higher dose of psilocin in the same cell type, with 100 μM treatment leading to a 57% extension in cellular lifespan.
The measured outcome was how many times cultured cells could divide before hitting senescence, not a reversal of biological age. Induction of senescence occurred in both vehicle and psilocin-treated cells, as both groups reached exhaustion of their proliferative potential. In other words, treated cells still aged and still became senescent. They simply took longer to get there.
The effect was replicated in a second cell type. When the experiment was repeated in adult human skin fibroblasts with 100 µM psilocin, cellular lifespan increased by approximately 51%, and markers of senescence decreased, accompanied by reductions in oxidative stress.
The animal arm was separate and produced a different number entirely. Aged 19-month female mice were treated with vehicle or psilocybin once per month for 10 months, initially given a low dose of 5 mg/kg followed by monthly high-dose 15 mg/kg treatment for a total of 10 treatments. The researchers used 19-month-old mice, roughly equivalent to 60 to 65 human years, to evaluate therapeutic potential as a clinically relevant anti-aging intervention.
At the end of the study period, 80% of psilocybin-treated mice (24 out of 30) were still alive, compared with 50% of control mice (14 out of 28), and this difference in survival was statistically significant.
The authors' own characterization uses the language of delay, not reversal. The study provides the first experimental evidence suggesting that psilocybin may impact multiple hallmarks of aging, including delayed senescence, preservation of telomere length, and enhanced DNA stability via increased DNA-damage responses.
Findings
✓ What's accurate 5
- The number 57% is real and appears in a real peer-reviewed paper in npj Aging, a Nature Portfolio journal.
- The cells were genuinely human, and the effect was dose-dependent and replicated across two fibroblast types.
- The study did find improvements in multiple recognized aging markers. Psilocin-treated cells showed lower senescence-associated β-galactosidase activity, reduced p16 and p21, increased proliferation markers PCNA and phosphorylated Rb, higher SIRT1, lower GADD45a, and reduced oxidative stress markers including decreased Nox4 and increased Nrf2.
- The mouse survival result was real and statistically significant.
- There was no sign of cancerous transformation. Psilocin-treated cells ultimately reached senescence and showed no evidence of uncontrolled, cancer-like growth under the tested conditions. ---
? What's uncertain 6
- Whether any of these effects occur in living humans at any dose. No human aging trial exists.
- Whether the cellular findings translate at physiologically achievable concentrations.
- Whether the mouse survival benefit would persist to full lifespan, since the study terminated at 50% control mortality.
- The magnitude of risk from repeated high-dose psilocybin over years in humans, which has never been tested.
- Whether the result replicates in male animals, other strains, or independent labs. As of this investigation I found no independent replication.
- The exact degree to which the unblinded design influenced the mouse morbidity and "healthier appearance" observations. ---
Sources
5 of 6 linked to records**Kato K, Kleinhenz JM, Shin YJ, Coarfa C, Zarrabi AJ, Hecker L. "Psilocybin treatment extends cellular lifespan and improves survival of aged mice." npj Aging 11, 55 (2025).** DOI: 10.1038/s41514-025-00244-x
**Emory University news release**
**Baylor College of Medicine news release**
**The Conversation, expert critique by a psychedelics dosing researcher**
**Peter Attia MD, critical technical review**
**ScienceAlert, ScienceDaily, Technology Networks, The Microdose**